Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook 
Shein Targets $26B-$27B Valuation for Hong Kong IPO 
Anthropic Revenue Run Rate Hits $65 Billion as IPO Plans Accelerate 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Add as a preferred source on Google
South Korean biopharmaceutical firm Celltrion Inc. will acquire the patent, trademark, and sales rights for 18 brands of Japan's Takeda Pharmaceutical in Asia-Pacific for 332.4 billion won.
The company will pursue the deal through its Singapore-based affiliate, hoping the complete the acquisition by year's end.
The nine markets covered by business rights include South Korea, Thailand, Malaysia, and Australia.
The 18 brands amassed a combined sales of $140 million in Asia-Pacific in 2018.
Celltrion plans to sell the brands through its affiliates Celltrion Pharma and Celltrion Healthcare.
The acquisition not only helps to stabilize the local supply of medication for hypertension, diabetes, and hyperlipidemia but also serves as Celltrion's first significant move in accelerating its push into the global market.
Celltrion had a net income of 298 billion won in 2019, a 17.5 percent surge from the year before.
